Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01460160 · ClinicalTrials.gov registry record · Phase 2
Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia
A Phase 2 study of Leukemia, Pediatric, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 106
- Enrollment target
- 20
- Study locations
NCT01460160: Completed Phase 2 study of Leukemia, Pediatric, sponsored by Bristol-Myers Squibb.
NCT01460160 is a Phase 2 study of Leukemia, Pediatric that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 106 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (20% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01460160, a Phase 2 study of Leukemia, Pediatric, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 106 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether Dasatinib when added to standard chemotherapy is effective and safe in the treatment of pediatric philadelphia chromosome positive acute lymphoblastic leukemia
Primary Outcome
3-year EFS rate is defined as the percentage of participants without event after 3 years since the start of study treatment. Events for EFS are defined as ANY first one of the following: * Lack of complete response in bone marrow * Relapse at any site * Development of second malignant neoplasm * Death from any cause
Conditions Studied
Interventions
- DRUG Dasatinib
Study Locations (20)
California
- Antranik Agop Bedros - Loma Linda
- Miller Children's and Women Hospital - Long Beach
- Children'S Hospital Of L.A. - Los Angeles
- Southern California Permanente Medical Group - Los Angeles
- Valley Children's Hospital - Madera
- Children's Hospital of Orange County - Orange
- Lpch & Sumc - Palo Alto
- Kaiser Medical Center - Roseville
- Ucsf - Hematology/Oncology - San Francisco
Florida
- Lee Memorial Health System - Fort Myers
- University Of Florida - Gainesville
- Nemours Children'S Clinic - Jacksonville
- Md Anderson Cancer Center Orlando - Orlando
Alabama
- University Of Alabama At Birmingham - Birmingham
Arizona
- Phoenix Children'S Hospital/Ctr. For Cancer & Blood Ctr. - Phoenix
Arkansas
- University Of Arkansas For Medical Sciences - Little Rock
Colorado
- Children'S Hospital Colorado - Aurora
Connecticut
- Connecticut Children's Medical Center - Hartford
Delaware
- A. I. Dupont Hospital For Children - Wilmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2012-04-13 |
| Est. Completion | 2021-06-01 |
| Phase | Phase 2 |
What the finished NCT01460160 record still lists
NCT01460160 is an interventional study that assigns participants to a tested intervention. The registered 106 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (20% lower).
The record links to 1 condition, with Leukemia, Pediatric appearing as the primary indexed condition, and to 1 intervention - of which Dasatinib is the first listed.
NCT01460160 names 20 study sites across 9 states, led by California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT01460160 about?
NCT01460160 is a clinical study titled "Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia". The purpose of this study is to determine whether Dasatinib when added to standard chemotherapy is effective and safe in the treatment of pediatric philadelphia chromosome positive acute lymphoblastic leukemia
What is the current status of trial NCT01460160?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 106 participants. The study started on 2012-04-13. Estimated completion is 2021-06-01.
What conditions does trial NCT01460160 study?
This clinical trial studies the following conditions: Leukemia, Pediatric.
What interventions are being tested in trial NCT01460160?
The interventions under investigation include: Dasatinib (DRUG).
Who is sponsoring clinical trial NCT01460160?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01460160 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01460160's enrollment target sits among peer trials
106 648th of 2000 higher than 1,351 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03181048 · 106 participants · NA
Clinical Trial of Concomitant Hip Arthroscopy During PAO
- NCT04682158 · 106 participants · Phase 2
Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma
- NCT04724018 · 106 participants · Phase 1
Sacituzumab Govitecan Plus EV in Metastatic UC
- NCT04798274 · 106 participants · NA
Role of GABAergic Transmission in Auditory Processing in Autism Spectrum Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI